Opendata, web and dolomites

ImplantFreeSpine

World’s first complete motion-preservation 'Implant-less' surgical correction for Scoliosis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ImplantFreeSpine project word cloud

Explore the words cloud of the ImplantFreeSpine project. It provides you a very rough idea of what is the project "ImplantFreeSpine" about.

safer    scoliosis    physical    restricting    care    spine    surgery    rate    alternative    complete    commercialisation    strategies    engage    market    disease    12    deformities       planning    optimisation    caused    elimination    deformity    intend    solution    permanently    medical    procedure    40    global    annual    post    conduct    rigid    cure    undergo    mobility    42    chronic    world    share    compound    arthritis    business    2022    life    diabetes    plan    grow    correction       invasive    quality    significantly    rehabilitation    introductory    capture    people    revenues    huge    obstructive    months    prototype    lifetime    international    treatment    complexity    directives    arrest    population    million    meeting    carry    model    phases    operative    additional    spinal    marketing    hospitalisation    time    fusion    reported    selling       techniques    earn    17    innovative    hypertension    permanent    holds    lung    severe    preserves    surgical    billion    shorter    period   

Project "ImplantFreeSpine" data sheet

The following table provides information about the project.

Coordinator
ATC GROUP LIMITED 

Organization address
address: UNIT 17 PERRYWOOD BUSINESS PARK HONEYCROCK LANE SALFORDS
city: REDHILL SURREY
postcode: RH1 5JQ
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website http://www.atcltd.co.uk/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2014
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-06-01   to  2015-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ATC GROUP LIMITED UK (REDHILL SURREY) coordinator 50˙000.00

Map

 Project objective

Scoliosis affects 2-3% of the world population i.e. about 12 million people in the EU. 20,000 cases of severe scoliosis are reported each year in the EU but less than 3,000 cases ever undergo surgery due to cost and complexity of the surgery. Severe cases of scoliosis are treated by spinal fusion; a major surgical procedure that makes the spine permanently rigid restricting physical activities and permanent arrest of spinal growth. The impact of spinal deformity caused by scoliosis on the quality of life before and after surgery is huge compared with other chronic conditions such as arthritis, chronic obstructive lung disease, diabetes and hypertension. Due to the need for an alternative method for better correction of scoliosis deformities we have developed novel devices and a highly innovative care model involving a safer and significantly less invasive, complete cure which preserves spinal mobility and growth potential. Our solution will result in reduced cost of treatment by over 40% because of shorter hospitalisation, reduced operating time, elimination of additional procedures and lifetime care costs. Spine surgery currently holds a €10.2 billion global market share and is estimated to grow at a compound annual growth rate of 6.9% to reach €17.5 billion by 2022. We aim to capture a market share of 0.1% in 5 years post commercialisation of our project and earn compound revenues of €42.5 million by selling our devices over the same period. In Phase 1 of this project we intend to conduct detailed planning of the testing and design optimisation phases, carry out a market study plan, identify and engage international partners and develop a draft business plan for use upon commercialisation within a period of 6 months. In Phase 2 we will develop an advanced prototype meeting relevant EU and US Medical Devices Directives, demonstrate surgical techniques, rehabilitation strategies, and post-operative procedures and also conduct introductory marketing of our devices.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IMPLANTFREESPINE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IMPLANTFREESPINE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More  

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More  

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More